SOPHiA GENETICS SA ROE 2020-2025 | SOPH
Current and historical return on equity (ROE) values for SOPHiA GENETICS SA (SOPH) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| SOPHiA GENETICS SA ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-09-30 | $-0.07B | $0.06B | -92.50% |
| 2025-06-30 | $-0.07B | $0.08B | -77.21% |
| 2025-03-31 | $-0.07B | $0.09B | -62.35% |
| 2024-12-31 | $-0.06B | $0.10B | -53.56% |
| 2024-09-30 | $-0.07B | $0.11B | -54.83% |
| 2024-06-30 | $-0.07B | $0.12B | -47.69% |
| 2024-03-31 | $-0.07B | $0.13B | -47.63% |
| 2023-12-31 | $-0.08B | $0.15B | -47.45% |
| 2023-09-30 | $-0.07B | $0.16B | -38.60% |
| 2023-06-30 | $-0.08B | $0.17B | -40.89% |
| 2023-03-31 | $-0.08B | $0.19B | -40.05% |
| 2022-12-31 | $-0.09B | $0.20B | -39.28% |
| 2022-09-30 | $-0.09B | $0.21B | -39.13% |
| 2022-06-30 | $-0.09B | $0.23B | -35.22% |
| 2022-03-31 | $-0.09B | $0.25B | -38.29% |
| 2021-12-31 | $-0.07B | $0.28B | -40.67% |
| 2021-09-30 | $-0.06B | $0.29B | -45.59% |
| 2021-06-30 | $-0.05B | $0.07B | -80.31% |
| 2021-03-31 | $-0.04B | $0.08B | -89.62% |
| 2020-12-31 | $-0.04B | $0.10B | -154.46% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.305B | $0.065B |
| SOPHiA GENETICS SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM(TM) Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. SOPHiA GENETICS SA is based in BOSTON. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.395B | 59.05 |
| Tempus AI (TEM) | United States | $14.291B | 0.00 |
| Doximity (DOCS) | United States | $11.985B | 53.33 |
| Hims & Hers Health (HIMS) | United States | $9.884B | 76.72 |
| IRhythm Technologies (IRTC) | United States | $5.815B | 0.00 |
| Hinge Health (HNGE) | United States | $3.560B | 0.00 |
| Privia Health (PRVA) | United States | $3.071B | 227.46 |
| Heartflow (HTFL) | United States | $2.895B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.406B | 39.82 |
| Enovis (ENOV) | United States | $1.800B | 9.51 |
| 10x Genomics (TXG) | United States | $1.679B | 0.00 |
| Omnicell (OMCL) | United States | $1.642B | 32.79 |
| Clover Health Investments (CLOV) | United States | $1.520B | 0.00 |
| Schrodinger (SDGR) | United States | $1.455B | 0.00 |
| Azenta (AZTA) | United States | $1.400B | 61.08 |
| Phreesia (PHR) | United States | $1.358B | 0.00 |
| Claritev (CTEV) | United States | $1.071B | 0.00 |
| Evolent Health (EVH) | United States | $0.746B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.697B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.632B | 0.00 |
| Talkspace (TALK) | United States | $0.576B | 114.67 |
| Veradigm (MDRX) | United States | $0.520B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.505B | 0.00 |
| Standard BioTools (LAB) | United States | $0.438B | 0.00 |
| Carlsmed (CARL) | United States | $0.322B | 0.00 |
| TruBridge (TBRG) | United States | $0.290B | 50.76 |
| CapsoVision (CV) | United States | $0.226B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.223B | 0.00 |
| Outset Medical (OM) | United States | $0.223B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.215B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.191B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.186B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.170B | 0.00 |
| CareCloud (CCLD) | United States | $0.125B | 5.67 |
| EUDA Health Holdings (EUDA) | Singapore | $0.119B | 0.00 |
| American Well (AMWL) | United States | $0.074B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.073B | 0.00 |
| Pulmonx (LUNG) | United States | $0.069B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.060B | 0.00 |
| HeartBeam (BEAT) | United States | $0.057B | 0.00 |
| 111 (YI) | China | $0.038B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.036B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.027B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.027B | 0.00 |
| Zhongchao (ZCMD) | China | $0.018B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |